The Ministry of Health of Russia has registered Molnupiravir Valenta, a COVID-19 drug developed by Valenta Pharm. This follows from the data from the State Register of Medicines.
According to the Registry, the antiviral drug in 200 mg capsules was registered on August 23.
In July, the Ministry of Health registered a molnupiravir-based COVID-19 drug produced by Tekhnologiia Lekarstv, a subsidiary of R-Pharm, in May; Geropharm’s drug for the treatment of coronavirus is also based on molnupiravir.
Medicines based on molnupiravir are included in the list of vital and essential drugs (VED) and can be used to treat coronavirus in adults.
